“The main reason for our consecutive export championship is the development of our production capacity through investments we have made.”
The 54th issue of Pharmaceutical Business Review International presents an exclusive interview with Ruşen Kalender, Chairman of the Board of World Medicine, one of Turkey’s prominent pharmaceutical manufacturers. Mr. Kalender shared insights into the company’s new…
FDA has cleared Prime Medicine’s Investigational New Drug application for PM359
Prime Medicine, a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PM359, submitted on March 29,…
FDA has approved BEQVEZ™ for the treatment of adults with moderate to severe hemophilia B
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding…
Late-breaking data supporting long-term safety & efficacy of atogepant for preventive treatment of migraine
AbbVie today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in…
MSK researchers show an experimental approach to treating pancreatic cancer with the mRNA-based therapeutic cancer vaccine candidate
New data presented by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran,…
Corinne M. Le Goff has been appointed as Viatris Chief Commercial Officer
Viatris today announced that Corinne M. Le Goff has joined the company as Chief Commercial Officer and will become a member of the company’s Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more…
Elecsys pTau217 assay received Breakthrough Device Designation from FDA
Roche announced that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the…
Bristol Myers Squibb releases 2023 ESG Report
Bristol Myers Squibb today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company’s ESG…
The inspiring “SO, Have You Found It?” campaign
Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “SO, Have You Found It?” campaign. This initiative spotlights the resilience of…
“The main reason for our consecutive export championship is the development of our production capacity through investments we have made.”
The 54th issue of Pharmaceutical Business Review International presents an exclusive interview with Ruşen Kalender, Chairman of the Board of World Medicine, one of Turkey’s prominent pharmaceutical manufacturers. Mr. Kalender shared insights into the company’s new investments supporting its ongoing…
FUJIFILM invests of $1.2 billion in its Large-Scale Cell Culture CDMO Business
FUJIFILM Corporation announced an investment of $1.2 billion in its Large-Scale Cell Culture CDMO Business to further expand the planned FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina, bringing the total investment in the facility to over…